Burkholderia Infections Market Analysis
Burkholderia Infections Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026
Burkholderia infections are caused by Burkholderia cepacia. It is a gram negative bacillus found in aquatic environment. It is a low virulent bacteria and is a frequent colonizer of fluids used in the hospitals such as IV fluid, irrigation solution etc. B. cepacia can cause health problems to some people such as patients suffering from weakened immune system or chronic lung diseases. Burkholderia infection symptom can vary widely in people, ranging from no symptoms to serious respiratory infection. Based on recent genomic subtyping techniques, Burkholderia infection can be transmitted from person to person. Patients with lung disease such as asthma, CFTR, and COPD are at high risk of suffering from Burkholderia infection. Burkholderia cepacia is resistant to multiple antibiotic such as aminoglycosides, antipseudomonal third-generation cephalosporins and antipseudomonal penicillins.
Global Burkholderia Infections Market Taxonomy
On the basis of drug type, the global market is classified as follows:
On the basis of distribution channel, the global market is classified as follows:
Prevalent Scenarios in Burkholderia infections Market
Increasing prevalence of lung diseases is expected to fuel growth of the Burkholderia infections market. The exact cause for asthma, cystic fibrosis is unknown, though the risk factors can be transferred generation from generation. As per the report of British Lung Foundation, in 2011, an estimated 1.2 million people are living with chronic obstructive pulmonary disease (COPD) and has grown by 27% in the last decade in the U.K. According to the U.S. Cystic Fibrosis Foundation, Europe accounted for the highest number of reported cases of cystic fibrosis in 2012. The growing cases of COPD, asthma and other lung diseases create high risk of burkholderia infection creating an opportunity for manufacturers. Burkholderia infections also cause complications such as soft tissue infections, urinary tract infection and surgical wound infections. It creates an opportunity for the manufacturers to focus on overall treatment. The increasing outbreaks of burkholderia infection has created focus towards the need for proper treatment procedure. Many organization and government policies have included burkholderia infection as one of the severe infections spread from healthcare facilities. Transmission of B. cepacia from contaminated medicines and medical devices. In 2005, CDC notified several states cluster of pneumonia and other infection caused by B. cepacia associated with contaminated mouthwash. In October, 2016, Nurse Assist Inc, recalled its normal saline flush IV syringes due to Burkholderia Cepacia bloodstream infection. FDA identified this as Class I recall, one of the most serious types of recall which may cause serious injuries or death. In 2004, Burkholderia Cepacia was linked to nosocomial infection among Intensive Care Unit patient and was associated with exposure to sublingual probes. The growing concerns related to contaminated medicines and medical devices are expected to create opportunity for product manufacturers in the burkholderia infections market. The effect of B. cepacia on people varies person to person which leaves the infection with no specific treatment. The unavailability of proper treatment creates hindrance to the overall market. North America is expected to account for maximum share of the global burkholderia infections market, owing to the better diagnostic facilities, increasing awareness and government initiative for early diagnosis and treatment of burkholderia infection. Europe is expected to be the second most lucrative burkholderia infections market.
Burkholderia Infections Market is Highly Fragmented
The market is highly fragmented due to the presence of many emerging players. Major players involved in the burkholderia infections market includes Novabiotics Ltd, iQur Ltd, Aridis Pharmaceuticals LLC, NanoBio Corporation, SUN pharma and others.
Continuous research and development activities are expected to facilitate growth of the burkholderia infections market. For instance, in February 2019, the National Institutes of Health (NIH) awarded a US$ 3.34 million grant to researchers at Case Western Reserve University School of Medicine to research and develop a technique for sensitizing Burkholderia multivorans, a common pathogen found in patients with lung diseases, to antibiotics.
Increasing number of investments by regulatory authorities, as well as private organisations to fund R&D activities is driving the market growth. In August 2019, the Biomedical Advanced Research and Development Authority (BARDA), announced a 2-year grant of up to US $20.7 million to VenatoRx Pharmaceuticals, who will then collaborate with BARDA’s Office of the Assistant Secretary for Preparedness and Response (ASPR), and the Department of Defense’s Defense Threat Reduction Agency (DTRA) to test the efficacy of VNRX-5133 compound in treating pathogens, specifically, melioidosis-causing bacterium Burkholderia pseudomallei.
Moreover, in October 2018, Synspira’s candidate therapy, SNSP113, received the orphan drug status from the U.S. Food and Drug Administration (FDA) for treating bacterial infections such as Burkholderia and non-tuberculous Mycobacteria in patients with cystic fibrosis (CF).